MA30959B1 - Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp - Google Patents

Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp

Info

Publication number
MA30959B1
MA30959B1 MA31938A MA31938A MA30959B1 MA 30959 B1 MA30959 B1 MA 30959B1 MA 31938 A MA31938 A MA 31938A MA 31938 A MA31938 A MA 31938A MA 30959 B1 MA30959 B1 MA 30959B1
Authority
MA
Morocco
Prior art keywords
triazole compounds
substituted pyrazole
ksp inhibitors
pharmaceutically acceptable
ksp
Prior art date
Application number
MA31938A
Other languages
English (en)
Inventor
Yi Xia
Kris G Mendenhall
Paul A Barsanti
Annette O Walter
David Duhl
Paul A Renhowe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30959B1 publication Critical patent/MA30959B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE DE NOUVEAUX COMPOSÉS DE PYRAZOLE ET DE TRIAZOLE SUBSTITUÉS REPRÉSENTÉS PAR LA FORMULE (I), ET DES SELS, DES ESTERS OU DES PROMÉDICAMENTS PHARMACEUTIQUEMENT ACCEPTABLES DE CEUX-CI, DES COMPOSITIONS DE CES DÉRIVÉS CONTENANT DES EXCIPIENTS PHARMACEUTIQUEMENT ACCEPTABLES AINSI QUE DES UTILISATIONS DE CELLES-CI.
MA31938A 2006-11-13 2009-06-01 Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp MA30959B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85896406P 2006-11-13 2006-11-13

Publications (1)

Publication Number Publication Date
MA30959B1 true MA30959B1 (fr) 2009-12-01

Family

ID=39144618

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31938A MA30959B1 (fr) 2006-11-13 2009-06-01 Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp

Country Status (32)

Country Link
US (2) US8129358B2 (fr)
EP (1) EP2091926B1 (fr)
JP (1) JP5264755B2 (fr)
KR (1) KR20090081020A (fr)
CN (1) CN101558049B (fr)
AR (1) AR063805A1 (fr)
AU (1) AU2007323998B2 (fr)
BR (1) BRPI0719002A2 (fr)
CA (1) CA2668661A1 (fr)
CL (1) CL2007003272A1 (fr)
CO (1) CO6382171A2 (fr)
CR (1) CR10787A (fr)
DO (1) DOP2009000106A (fr)
EA (1) EA017748B1 (fr)
EC (1) ECSP099326A (fr)
ES (1) ES2557478T3 (fr)
GE (1) GEP20125389B (fr)
GT (1) GT200900122A (fr)
HN (1) HN2009000968A (fr)
IL (1) IL198471A0 (fr)
MA (1) MA30959B1 (fr)
MX (1) MX2009005071A (fr)
NI (1) NI200900084A (fr)
NO (1) NO20092226L (fr)
NZ (1) NZ576640A (fr)
PE (1) PE20081169A1 (fr)
SM (1) SMP200900045B (fr)
TN (1) TN2009000178A1 (fr)
TW (1) TW200831480A (fr)
UA (1) UA97256C2 (fr)
WO (1) WO2008063912A1 (fr)
ZA (1) ZA200902940B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129358B2 (en) * 2006-11-13 2012-03-06 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
JP2010515687A (ja) * 2007-01-05 2010-05-13 ノバルティス アーゲー キネシンスピンドルタンパク質阻害剤（ｅｇ−５）としてのイミダゾール誘導体
US8748626B2 (en) 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
US8546434B2 (en) * 2010-04-15 2013-10-01 Novartis Ag Triazole compounds as KSP inhibitors
CA2892919A1 (fr) * 2012-12-05 2014-06-12 Merck Sharp & Dohme Corp. Procede de preparation d'inhibiteurs de transcriptase inverse
WO2014151030A1 (fr) * 2013-03-15 2014-09-25 Novartis Ag Inhibiteurs de la prolifération cellulaire et leurs conjugués
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
EP3077376B1 (fr) 2013-12-04 2019-10-16 Merck Sharp & Dohme Corp. Procédé de préparation d'inhibiteurs de transcriptase inverse
WO2016020791A1 (fr) 2014-08-05 2016-02-11 Novartis Ag Conjugués anticorps ckit-médicament
EP3386973B1 (fr) * 2015-12-11 2020-08-12 Syngenta Participations AG Dérivés de 1,2,4-triazole actif sur le plan pesticide
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5185450A (en) 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
JP2002541146A (ja) 1999-04-02 2002-12-03 ニューロゲン コーポレイション アリールおよびヘテロアリール融合のアミノアルキル−イミダゾール誘導体および糖尿病薬としてのその使用
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ES2263501T3 (es) 1999-10-27 2006-12-16 Cytokinetics, Inc. Procedimiento y composiciones que utilizan quinazolinonas.
CA2425185A1 (fr) 2000-10-06 2002-04-11 Stephane De Lombaert Derives de benzimidazole et d'indole en tant que modulateurs des recepteurs de la corticoliberine
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
US6992082B2 (en) 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
AU2002363429B2 (en) 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2466033A1 (fr) 2001-11-08 2003-05-15 The University Of Chicago Methode de traitement de troubles lies a un taux de cholesterol eleve
WO2003043995A1 (fr) 2001-11-20 2003-05-30 Cytokinetics, Inc. Procede de racemisation de quinazolinones chirales
CA2467726A1 (fr) 2001-12-06 2003-06-19 Merck & Co., Inc. Inhibiteurs mitotiques de la kinesine
US7378411B2 (en) 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
WO2003049679A2 (fr) 2001-12-06 2003-06-19 Merck & Co., Inc. Inhibiteurs mitotiques de la kinésine
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
AU2002363960B2 (en) 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US20040259936A1 (en) * 2001-12-07 2004-12-23 Nagarkatti Leonard C Treatment of neoplasia
WO2003059289A2 (fr) 2002-01-10 2003-07-24 Neurogen Corporation Ligands recepteurs de l'hormone de concentration de la melanine: analogues de benzoimidazole substitue
AU2003213092A1 (en) 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
JP2005530785A (ja) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
EP1503993A4 (fr) 2002-05-09 2006-05-03 Cytokinetics Inc Composes, compositions et procedes
AU2003290507A1 (en) 2002-05-10 2004-04-08 Cytokinetics, Inc. Compounds, compositions and methods
EP1513820A4 (fr) 2002-05-23 2006-09-13 Cytokinetics Inc Composes, compositions et procedes
AU2003231799A1 (en) 2002-05-23 2003-12-12 Merck & Co., Inc. Mitotic kinesin inhibitors
KR20050010515A (ko) 2002-06-14 2005-01-27 머크 앤드 캄파니 인코포레이티드 유사분열 키네신 억제제
EP1515949B1 (fr) 2002-06-14 2007-03-14 Merck & Co., Inc. Inhibiteurs de kinesine mitotique
GB0214139D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
EP1551962A4 (fr) 2002-07-08 2007-08-01 Merck & Co Inc Site de liaison de la kinesine mitotique
EP1539727B1 (fr) 2002-07-17 2009-02-18 Cytokinetics, Inc. Composes, compositions et methodes pour le traitement des maladies proliferatives cellulaires
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
AU2003262747A1 (en) 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
EP1620092A4 (fr) 2003-05-07 2008-04-16 Cytokinetics Inc Composes, compositions et methodes
EP1622878A4 (fr) 2003-05-15 2008-04-09 Cytokinetics Inc Composes, compositions et procedes
PT1732926E (pt) 2004-04-06 2009-04-03 Novartis Vaccines & Diagnostic Inibidores de cinesinas mitóticas
JP2008502721A (ja) * 2004-05-21 2008-01-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 分裂キネシンインヒビターとしての置換キノリン誘導体
JP4836280B2 (ja) * 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
EP1807399A2 (fr) 2004-10-19 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Derives d'indole et de benzimidazole
US7829589B2 (en) * 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
US8129358B2 (en) * 2006-11-13 2012-03-06 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors

Also Published As

Publication number Publication date
JP5264755B2 (ja) 2013-08-14
WO2008063912A1 (fr) 2008-05-29
HN2009000968A (es) 2011-10-25
CR10787A (es) 2009-07-02
CO6382171A2 (es) 2012-02-15
EP2091926B1 (fr) 2015-10-21
ECSP099326A (es) 2009-06-30
CN101558049A (zh) 2009-10-14
PE20081169A1 (es) 2008-09-24
US20080200462A1 (en) 2008-08-21
AR063805A1 (es) 2009-02-18
DOP2009000106A (es) 2009-05-31
KR20090081020A (ko) 2009-07-27
SMP200900045B (it) 2010-03-01
TW200831480A (en) 2008-08-01
AU2007323998A1 (en) 2008-05-29
US8129358B2 (en) 2012-03-06
GEP20125389B (en) 2012-01-25
BRPI0719002A2 (pt) 2013-12-17
NI200900084A (es) 2010-01-29
SMAP200900045A (it) 2009-07-14
EA200900631A1 (ru) 2009-12-30
EA017748B1 (ru) 2013-02-28
CL2007003272A1 (es) 2008-03-24
NZ576640A (en) 2011-10-28
JP2010509365A (ja) 2010-03-25
NO20092226L (no) 2009-08-12
MX2009005071A (es) 2009-05-25
AU2007323998B2 (en) 2011-09-22
CA2668661A1 (fr) 2008-05-29
GT200900122A (es) 2011-09-14
CN101558049B (zh) 2012-08-15
TN2009000178A1 (en) 2010-10-18
IL198471A0 (en) 2010-02-17
US7902240B2 (en) 2011-03-08
ES2557478T3 (es) 2016-01-26
EP2091926A1 (fr) 2009-08-26
ZA200902940B (en) 2010-05-26
US20100034813A1 (en) 2010-02-11
UA97256C2 (ru) 2012-01-25

Similar Documents

Publication Publication Date Title
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA31080B1 (fr) Dérivés cyclisés en tant qu'inhibiteurs d'eg-5.
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA30781B1 (fr) Inhibiteur de kinase
MA29909B1 (fr) Derives de pyridazine
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
MA30166B1 (fr) Imidazoles substitues et leur utilisation comme pesticides.
TN2009000544A1 (fr) Derives de benzimidazole
MA31580B1 (fr) Derives de bicyclolactames substitués
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
TW200612958A (en) Substituted imidazole derivatives
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
TW200833675A (en) Nicotinamide derivatives
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA32151B1 (fr) Derives de 2-aza-bicyclo[2.2.1]heptane
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
MA30819B1 (fr) Nouvelle diphenylazetidinone substituee par l'acide piperazin-1-sulfonique et presentant des proprietes pharmacologiques ameliorees
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
WO2007109578A3 (fr) Gamma lactames substitues en tant qu'agents therapeutiques
WO2007126900A3 (fr) Agents antifongiques